Screener
Celldex Therapeutics CLDX Intangibles (Net)
Intangibles (Net) at other companies
Other financials
Where this comes from
Reported directly by Celldex Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IntangibleAssetsNetExcludingGoodwill.
The source filing: Celldex Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091984
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Total current assets | 724,931 | 534,664 |
| Property and equipment, net | 9,756 | 5,334 |
| Operating lease right-of-use assets, net | 5,038 | 2,437 |
| Intangible assets | 27,190 | 27,190 |
| Other assets | 15,434 | 13,358 |
| Total assets | $782,349 | $582,983 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: |
Item 1. Unaudited Financial Statements
FAQ
- What is Celldex Therapeutics's intangibles (net)?
- Celldex Therapeutics (CLDX) reported intangibles (net) of $27.19M in Q2 2026.
- How has Celldex Therapeutics's intangibles (net) changed year-over-year?
- Celldex Therapeutics's intangibles (net) decreased by 0.0% year-over-year, from $27.19M to $27.19M.
- What is the long-term trend for Celldex Therapeutics's intangibles (net)?
- Over 5 years (2020 to 2025), Celldex Therapeutics's intangibles (net) has grown at a -2.4% compound annual growth rate (CAGR), from $30.69M to $27.19M.
- What does intangibles (net) mean?
- Identifiable intangible assets (patents, trademarks, customer relationships, technology) net of accumulated amortization — excluding goodwill.
Ask your AI about Celldex Therapeutics's intangibles (net).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude